Newsletter
Aug 26, 2026
•
4 min read
Plus: Zymeworks banks $250M and falls 7%. Bristol Myers walks.
Aug 25, 2026
5 min read
Alzheimer's gets a blood test, Regenxbio gets five bad MRIs, Munich opens Friday.
Aug 24, 2026
Non-incretin obesity, a GOP letter aimed at China trial data, and Capricor’s PDUFA comes and goes.
Aug 21, 2026
Roche commits $750M to a plant that won't fill a syringe until 2031.
Aug 20, 2026
Moderna adds $44B of market cap in a session, and the FDA hands out two firsts.
Aug 19, 2026
Overton heads for a Senate fight, and a third China trial death surfaces.
Aug 18, 2026
Duravyu's primary miss, a PD-1/VEGF curve that shrank, and AstraZeneca finally printing a win.
Aug 17, 2026
Capricor doubles on an FDA reprieve, and Redx backs into Nasdaq with $125M.
Aug 14, 2026
Zipalertinib clears Phase 3, and the FDA puts a price on where you run Phase 1.
Aug 13, 2026
Plus: PTC raids the Sangamo estate for $111M, and Vykat XR draws heat.
Aug 12, 2026
Three drugmakers take Illinois to court, and crossover money backs an FSHD editor.
Aug 11, 2026
Jazz swings for rare epilepsy, Trump targets childhood shots, and Sionna hands Vertex a free pass.
Aug 10, 2026
Grail's failed test finally gets a date with an FDA panel.
Aug 7, 2026
Two rejections, one adcomm, one approval — plus $450M for a drug that reads out in 2029.
Aug 6, 2026
Reuters says the AstraZeneca-Bristol Myers talks are off. Also: two IPOs price.
Aug 5, 2026
Hinge expands into digestive care, Gilead's Yeztugo beats, and Merck leans harder into the Keytruda combo play.
Aug 4, 2026
Curium takes Lantheus private, Pathos writes a $125M check, and Jazz raises the year.
Aug 3, 2026
Novo’s ZEUS misses on 6,300 patients. Apnimed’s debut pops 56%.
Jul 31, 2026
FDA advisers back Replimune, Alnylam gets cut down to size, and the first pharma tariffs skip their Friday deadline.
Jul 30, 2026
J&J swings for Sail, Capricor gets a 9-3 adcomm rebuke, and reverse mergers still find $478M.
Jul 29, 2026
J&J writes a $5.5B cheque to close the talc book, Altimmune's GLP-1 lands in the drinking clinic, and Yokohama sells out before it opens.
Jul 28, 2026
An OS win and a rare-disease faceplant for AstraZeneca, an FDA ambush on Capricor a day before its panel, and MapLight's 66% haircut on the Cobenfy comp.
Jul 27, 2026
argenx bags an anti-CD122 antibody for $2.2B, and CHMP splits its rare-disease verdicts.
Jul 24, 2026
Retatrutide clears the bar but not the one that mattered, J&J posts an 0.11, and gene editing prices an IPO.
Jul 23, 2026
FDA cleared GSK's $10.6B Nuvalent asset two months early. Arrowhead cut triglycerides 81%.
